

Michael R Clark

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5047754/publications.pdf>

Version: 2024-02-01

69
papers

2,754
citations

172457

29
h-index

175258

52
g-index

73
all docs

73
docs citations

73
times ranked

2333
citing authors

#	ARTICLE	IF	CITATIONS
1	Reduced FcRn-mediated transcytosis of IgG2 due to a missing Glycine in its lower hinge. <i>Scientific Reports</i> , 2019, 9, 7363.	3.3	21
2	Human IgG lacking effector functions demonstrate lower FcRn-binding and reduced transplacental transport. <i>Molecular Immunology</i> , 2018, 95, 1-9.	2.2	15
3	IgG Subclasses Targeting the Flagella of <i>Salmonella Enterica</i> Serovar Typhimurium Can Mediate Phagocytosis and Bacterial Killing. <i>Journal of Vaccines & Vaccination</i> , 2016, 07, .	0.3	11
4	Human IgG1 antibodies suppress angiogenesis in a target-independent manner. <i>Signal Transduction and Targeted Therapy</i> , 2016, 1, .	17.1	30
5	The INNs and outs of antibody nonproprietary names. <i>MAbs</i> , 2016, 8, 1-9.	5.2	48
6	Low-affinity Fc γ R interactions can decide the fate of novel human IgG-sensitized red blood cells and platelets. <i>European Journal of Immunology</i> , 2014, 44, 905-914.	2.9	3
7	Clearance of Human IgG1-Sensitized Red Blood Cells In Vivo in Humans Relates to the In Vitro Properties of Antibodies from Alternative Cell Lines. <i>PLoS ONE</i> , 2014, 9, e109463.	2.5	1
8	Regulation unmasked by activation. <i>Nature Immunology</i> , 2013, 14, 696-697.	14.5	2
9	Quantification of the effects of antibodies on the extra- and intracellular dynamics of <i>Salmonella enterica</i> . <i>Journal of the Royal Society Interface</i> , 2013, 10, 20120866.	3.4	7
10	Recombinant HPA-1a antibody therapy for treatment of fetomaternal alloimmune thrombocytopenia: proof of principle in human volunteers. <i>Blood</i> , 2013, 122, 313-320.	1.4	34
11	Human IgG isotypes and activating Fc γ receptors in the interaction of <i>Salmonella enterica</i> serovar Typhimurium with phagocytic cells. <i>Immunology</i> , 2011, 133, 74-83.	4.4	38
12	Expression of human Fc γ R1a as a GPI-linked molecule on CHO cells to enable measurement of human IgG binding. <i>Journal of Immunological Methods</i> , 2010, 354, 20-33.	1.4	16
13	An immunoglobulin E-reactive chimeric human immunoglobulin G1 anti-idiotypic antibody inhibits basophil degranulation through cross-linking of Fc ϵ R1 with Fc γ R1b. <i>Clinical and Experimental Allergy</i> , 2008, 38, 313-319.	2.9	16
14	PECAM-1 Polymorphism Affects Monocyte Adhesion to Endothelial Cells. <i>Transplantation</i> , 2008, 85, 471-477.	1.0	21
15	Developing recombinant HPA-1a-specific antibodies with abrogated Fc γ receptor binding for the treatment of fetomaternal alloimmune thrombocytopenia. <i>Journal of Clinical Investigation</i> , 2008, 118, 2929-38.	8.2	42
16	Recombinant Human HPA-1A Antibodies for Treatment of Fetomaternal Alloimmune Thrombocytopenia (FMAIT): Proof of Principle in An in Vivo Murine Model and Human Volunteer Studies. <i>Blood</i> , 2008, 112, 85-85.	1.4	4
17	American Gastroenterological Association Consensus Development Conference on the Use of Biologics in the Treatment of Inflammatory Bowel Disease, June 21-23, 2006. <i>Gastroenterology</i> , 2007, 133, 312-339.	1.3	197
18	Intravascular survival of red cells coated with a mutated human anti-D antibody engineered to lack destructive activity. <i>Blood</i> , 2006, 107, 2619-2626.	1.4	30

#	ARTICLE	IF	CITATIONS
19	Evaluation of New Treatments in Radiation Oncology. JAMA - Journal of the American Medical Association, 2005, 293, 970.	7.4	78
20	Empowering the inventor—the case of monoclonal antibodies. Nature Biotechnology, 2005, 23, 1047-1049.	17.5	3
21	Function-blocking antibodies to human vascular adhesion protein-1: A potential anti-inflammatory therapy. European Journal of Immunology, 2005, 35, 3119-3130.	2.9	28
22	A Chimeric Antibody to Varicella-Zoster Virus Glycoprotein E. Hybridoma, 2005, 24, 50-54.	0.4	3
23	The effect of recombinant IgG antibodies against the leucine-33 form of the platelet α 2b integrin (HPA-1a) on platelet function. Thrombosis and Haemostasis, 2004, 91, 743-754.	3.4	21
24	Differential binding to human Fc γ RIIa and Fc γ RIIb receptors by human IgG wildtype and mutant antibodies. Molecular Immunology, 2003, 40, 585-593.	2.2	68
25	The contrasting IgG-binding interactions of human and herpes simplex virus Fc receptors. Biochemical Society Transactions, 2002, 30, 495-500.	3.4	28
26	The production and characterisation of a chimaeric human IgE antibody, recognising the major mite allergen Der p 1, and its chimaeric human IgG1 anti-idiotypic. Journal of Clinical Pathology, 2002, 55, 315-324.	1.9	19
27	Characterisation of a mouse monoclonal anti-idiotypic reactive with a V region sequence commonly used by human immunoglobulins. Journal of Clinical Pathology, 2000, 53, 77-82.	1.9	7
28	A rapid one-stage whole-blood HPA-1a phenotyping assay using a recombinant monoclonal IgG1 anti-HPA-1a. British Journal of Haematology, 2000, 108, 440-447.	2.5	40
29	Antibody humanization: a case of the "Emperor's new clothes"? Trends in Immunology, 2000, 21, 397-402.	2.5	246
30	Recombinant antibodies, by Frank Breitling and Stefan DÄ¼bel. Trends in Immunology, 2000, 21, 412.	7.5	0
31	In Vivo Detection of Vascular Adhesion Protein-1 in Experimental Inflammation. American Journal of Pathology, 2000, 157, 463-471.	3.8	101
32	Chimeric and humanised—misunderstood. Lancet, The, 2000, 355, 1557.	13.7	2
33	Immunology Interactive 2.0 CD-ROM. Trends in Immunology, 1999, 20, 56.	7.5	1
34	The use of phage-peptide libraries to define the epitope specificity of a mouse monoclonal anti-Der p 1 antibody representative of a major component of the human immunoglobulin E anti-Der p 1 response. Clinical and Experimental Allergy, 1999, 29, 1563-1571.	2.9	32
35	Rapid phenotyping of HPA-1a using either diabody-based hemagglutination or recombinant IgG1-based assays. Transfusion, 1999, 39, 781-789.	1.6	24
36	Recombinant human IgG molecules lacking Fc γ 3 receptor binding and monocyte triggering activities. European Journal of Immunology, 1999, 29, 2613-2624.	2.9	173

#	ARTICLE	IF	CITATIONS
37	Recombinant human IgG molecules lacking Fc γ 3 receptor I binding and monocyte triggering activities. , 1999, 29, 2613.		3
38	Activation of complement by human IgG1 and human IgG3 antibodies against the human leucocyte antigen CD52. Immunology, 1998, 93, 595-600.	4.4	34
39	Primary sequence and molecular model of the variable region of a mouse monoclonal anti-Der p 1 antibody showing a similar epitope specificity as human IgE. Clinical and Experimental Allergy, 1998, 28, 1427-1434.	2.9	10
40	The influence of the hinge region length in binding of human IgG to human Fc γ 3 receptors. Human Immunology, 1998, 59, 720-727.	2.4	40
41	One IgG receptor, two different functions. Lancet, The, 1996, 347, 1104.	13.7	0
42	IgG Effector Mechanisms. Chemical Immunology and Allergy, 1996, 65, 88-110.	1.7	80
43	IgG Effector Mechanisms. Chemical Immunology and Allergy, 1996, 65, 88-110.	1.7	42
44	Two different roles for the neonatal IgG Fc receptor FcRn?. Trends in Immunology, 1996, 17, 251.	7.5	0
45	CD8 T cell activation after intravenous administration of CD3 γ –CD19 bispecific antibody in patients with non-Hodgkin lymphoma. Cancer Immunology, Immunotherapy, 1995, 40, 390-396.	4.2	43
46	Clinical Experience with CD3 X CD19 Bispecific Antibodies in Patients with B Cell Malignancies. Stem Cells and Development, 1995, 4, 433-437.	1.0	63
47	CD8 T cell activation after intravenous administration of CD3 γ 1/2CD19 bispecific antibody in patients with non-Hodgkin lymphoma. Cancer Immunology, Immunotherapy, 1995, 40, 390-396.	4.2	10
48	Unprimed CD4+ and CD8+ T cells can be rapidly activated by a CD3 γ –CD19 bispecific antibody to proliferate and become cytotoxic. Cancer Immunology, Immunotherapy, 1994, 39, 391-396.	4.2	23
49	Principles of cellular and molecular immunology. Trends in Cell Biology, 1994, 4, 70.	7.9	0
50	The generation of a humanized, non-mitogenic CD3 monoclonal antibody which retains in vitro immunosuppressive properties. European Journal of Immunology, 1993, 23, 403-411.	2.9	213
51	Structural motifs involved in human IgG antibody effector functions. European Journal of Immunology, 1993, 23, 1098-1104.	2.9	139
52	The use of mouse/human chimaeric antibodies to investigate the roles of different antibody isotypes, including IgA2, in the killing of Schistosoma mansoni schistosomula by eosinophils. Parasite Immunology, 1993, 15, 181-185.	1.5	47
53	A humanized monovalent CD3 antibody which can activate homologous complement. European Journal of Immunology, 1991, 21, 2717-2725.	2.9	48
54	Monoclonal-Antibody Therapy in Systemic Vasculitis. New England Journal of Medicine, 1990, 323, 250-254.	27.0	246

#	ARTICLE	IF	CITATIONS
55	A simple method for measuring patient anti-globulin responses against isotypic or idiotypic determinants. <i>Journal of Immunological Methods</i> , 1990, 127, 19-24.	1.4	43
56	Development and Clinical Experience with Humanised Monoclonal Antibodies. <i>Developments in Biotherapie</i> , 1990, , 195-199.	0.1	0
57	The improved lytic function and in vivo efficacy of monovalent monoclonal CD3 antibodies. <i>European Journal of Immunology</i> , 1989, 19, 381-388.	2.9	42
58	The potential of hybrid antibodies secreted by hybrid-hybridomas in tumour therapy. <i>International Journal of Cancer</i> , 1988, 41, 15-17.	5.1	15
59	Hybrid Antibodies for Therapy. <i>Chemical Immunology and Allergy</i> , 1988, 45, 31-49.	1.7	8
60	Monoclonal Antibodies for Immunosuppression. <i>Chemical Immunology and Allergy</i> , 1988, 45, 16-30.	1.7	4
61	BLOCKING OF CYTOTOXIC T CELL FUNCTION BY MONOCLONAL ANTIBODIES AGAINST THE CD45 ANTIGEN		